US 11,919,911 B2
Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators
Sung David C. Kim, Westwood, MA (US); Zaixing Li, Shanghai (CN); Chui Lu, Shanghai (CN); Danuta Lubicka, Peabody, MA (US); James Neef, Stow, MA (US); Hye-Yeon Park, Arlington, MA (US); Tejaskumar Pankajbhai Pathak, Boston, MA (US); Amir Masoud Sadaghiani, Dover, MA (US); and Xilin Zhou, Arlington, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Jun. 11, 2021, as Appl. No. 17/346,006.
Claims priority of application No. PCT/CN2020/096177 (WO), filed on Jun. 15, 2020.
Prior Publication US 2021/0395261 A1, Dec. 23, 2021
Int. Cl. C07D 491/048 (2006.01); C07D 221/04 (2006.01)
CPC C07D 491/048 (2013.01) [C07D 221/04 (2013.01); C07B 2200/13 (2013.01)] 22 Claims
 
1. A compound according to formula (I) or a pharmaceutically acceptable salt thereof

OG Complex Work Unit Chemistry
wherein:
A is O;
R1 is H or F;
R2 is H or F; and
R3 is methyl substituted with 1 or 3 F, ethyl substituted with 1 to 3 F, or cyclopropyl optionally substituted with 1 to 3 F.